Evidence Hub

The effects of Bifidobacterium animalis subsp. lactis BLa80 on glycemic control and gut microbiota in patients with T2DM: a randomized, double-blind, placebo-controlled trial

Zhao C, Lu X, Deng X, Xia W, Sun T, Huo D, Shi L

Journal of diabetes and its complications, 2025

80 participants · 2 citations

Abstract

To evaluate the effect of Bifidobacterium subsp. lactis BLa80 on glycemic control and gut microbiota composition in patients with type 2 diabetes mellitus (T2DM), a randomized, placebo-controlled clinical trial was conducted in 80 patients. Participants were randomly assigned to receive either BLa80 supplementation or placebo (n = 40 per group) in addition to standard metformin therapy for 12 weeks. Fasting blood and stool samples were collected at baseline and at the end of the intervention. The results showed that BLa80 supplementation significantly reduced fasting blood glucose and high-density lipoprotein cholesterol (HDL-C) levels, while low-density lipoprotein cholesterol (LDL-C) levels were increased. Furthermore, BLa80 modulated the diversity and composition of the gut microbiota after 12 weeks of intervention. In conclusion, BLa80 supplementation may improve glycemic control and modulate the gut microbiota in patients with T2DM, suggesting its potential as an adjunctive therapy in diabetes management.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 80 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free